tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Y-mAbs Therapeutics reports Q1 EPS (15c), consensus (14c)

Reports Q1 revenue $19.9M, consensus $22.22M.”We continued to make meaningful progress across our commercial and clinical development initiatives during the first quarter of this year,” said Mike Rossi, President and Chief Executive Officer. “On the commercial front, the first quarter of 2024 marked the highest quarter of U.S. demand for DANYELZA(R) (naxitamab-gqgk) since its initial launch. Our recorded net product revenues in the first quarter were primarily driven by heightened demand across both new and existing U.S. accounts. DANYELZA remains a leading anti-GD2 therapy, and we continue to believe in its potential to serve patients beyond the high-risk relapse/refractory neuroblastoma market. In addition, we are highly encouraged by the clinical advancement of our Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy (“PRIT”) Technology platform. With the potential to deliver optimal therapy with minimal toxicity, increase physician participation in the patient treatment journey, and leverage existing infrastructure as a potentially isotope-agnostic platform, we believe SADA PRIT has the potential to make a positive and lasting impact on patient care.”

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1